Weave Bio raises $20M in Series A funding. Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding. The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. The company intends to use the funds to accelerate product development and expand its commercial team. In details, Weave Bio will: * complete its coverage of the entire regulatory lifecycle of therapeutics, inclusive of market applications (NDA/BLA), responses to health authority questions (HAQ/RTQ), and post-market updates and submissions; * Expand into global markets beyond the U.S. FDA, including Europe, Japan, and Latin America; and * Build advanced AI capabilities that will provide insights into therapeutic portfolios and empower strategic decision-making across the drug development process. Led by Brandon Rice, CEO and co-founder, Weave Bio provides an AI-native, cloud-based, software platform that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed.

Weave Bio has secured $20 million in Series A funding, led by USVP with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. This brings the company's total capital raised to $36 million. The funding will be used to enhance Weave's AI-native regulatory platform, expand global market reach, and build advanced AI capabilities. The platform aims to streamline regulatory workflows for pharmaceutical companies, biotech firms, and regulatory consultants.

Parexel announces AI partnership with Weave Bio to accelerate regulatory submission processes.